Candel Therapeutics Inc (NASDAQ: CADL) announced updated activity data from its ongoing, open-label, phase 2 trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage III/IV non-small cell l
Gainers
Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak Pharmacy.
Candel Therapeutics Inc (NASDAQ: CADL) announced new data from an ongoing phase 1 trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients with high-grade glioma that has recurred after